LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– #AI–Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating ant
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
